Displaying 1–25 of 10796 results for
INTERPHEX 2019 conference recap
Insys Therapeutics has agreed to pay $225 million to settle the federal government's criminal and civil investigations into the company's marketing practices for it's fentanyl-based medication, Subsys.
The Trump administration announced that the federal government would sharply limit federal spending on medical research that uses tissue from aborted fetuses.
For the first time ever, the FDA has approved a medication to treat cluster headaches.
A few years ago, researchers inside Pfizer reportedly discovered that one of the company’s blockbuster drugs could be a breakthrough treatment for Alzheimer’s.
The German drugmaker will be providing an upfront payment, pharmaceutical R&D support and an investment $60 million.
The previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
The commercialization of a new drug follows a rigid path and applying for FDA approval can be a minefield of challenges. Here are expert tips for nailing your application.
Automation: Reaping the benefits from improved instrument verification and calibration procedures.
A treatment that targets a specific genetic mutation has proven to be effective in shrinking tumors in some patients with advanced lung cancer.
On Friday, the FDA listened to testimonies from over 100 stakeholders in the growing market for CBD, a non-psychoactive compound found in marijuana.
Gilead's Kite announced findings from new analyses of CAR-T treatments at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
A Kaiser Health News investigation claims that the Orphan Drug Act is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already being taken by millions.
For pharma, it pays to update facilities and mindsets
Pfizer is shifting its attention to remoter regions of China in an effort to offset the impact of government price-cutting policies on sales of its aging blockbusters.
Ayala Pharmaceuticals has raised $30 million in a series B funding round, led by Novartis.
New technology allows equipment data to be aggregated and analyzed, facilitating best practices across all batches.
BioMarin Pharmaceutical reported this week that the effects of its new gene therapy may diminish over time.
A new study has revived the debate over whether or not cancer drugs fast-tracked through the FDA’s accelerated approvals program actually help patients.
Pharma Manufacturing sat down with tableting expert, Alex Bunting, I Holland, to discuss common tablet manufacturing problems and fixes.
Vraylar is also approved for schizophrenia in adults and for manic or mixed episodes associated with bipolar I disorder.
The drug, Piqray, is the first new drug application approved under the FDA Oncology Center of Excellence Real-Time Oncology Review pilot program.
A group of scientists say they are getting closer to developing a vaccine that could help prevent strep throat and scarlet fever.